Drug pricing

News

AstraZeneca has become the second pharma group to reach an agreement with the Trump administration on Most Favoured Nation (MFN) drug pricing.

Market Access

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

News

Changes to the threshold used by NICE to measure cost-effectiveness could be on the way as part of a plan that would raise NHS spending on medicines.

News

Donald Trump looks set to delay the introduction of his tariffs on pharma imports in order to negotiate more deals with drugmakers on drug pricing.

News

At the White House today, President Trump and Pfizer CEO Albert Bourla announced the first of many deals to secure MFN drug prices for US consumers.

News

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.